
By the Scientific Team of Fondazione Valter Longo
Prostate cancer is the second most common cancer among men.1 Its high incidence, disease burden, and mortality make it a major global health concern. It is a hormone-sensitive cancer, and patients are particularly susceptible to developing metabolic syndrome due to the well-established association between prostate cancer and weight gain, as well as related comorbidities such as diabetes.2 Androgen deprivation therapy (ADT), which uses drugs designed to block the effects of testosterone and related androgens, is an important strategy in the management of prostate cancer,3 but these drugs are also known to cause significant metabolic side effects. As a result, patients with prostate cancer may develop multiple features of metabolic syndrome induced by the use of these drugs.
In addition, obesity is a risk factor for the development of aggressive disease and for increased mortality.4 Recent literature reports that even a 5% weight gain after diagnosis is associated with more than a doubling of the relative risk of dying from prostate cancer (hazard ratio [HR] 1.65, +65%) and with a 27% higher risk of all-cause (but not cardiovascular) mortality (HR 1.27), suggesting that this link may relate primarily to tumor progression.5’6
A lifestyle modification aimed at weight loss could therefore delay or prevent disease progression, in addition to improving these patients’ quality of life. At present, there are still no standard nutritional intervention recommendations specific to the management of prostate cancer.7
Fasting and the fasting-mimicking diet, which have been studied for their potential to mitigate chemotherapy-related toxicity and improve metabolic risk factors, can induce nutritional ketosis, promoting important changes in metabolic pathways that could also result in reduced tumor growth.
Studies in mouse models have shown that a periodic 4-day fasting-mimicking diet, administered twice a month and alternated with a normal diet, leads to significant reductions in body weight and visceral fat, as well as a 45% reduction in tumor incidence and a delay in tumor development.8 Three cycles of the fasting-mimicking diet proved effective in reducing body weight, total and trunk body fat, blood pressure, and IGF-1 compared with a normal diet in a randomized phase 2 study involving 100 participants with no diagnosed medical conditions.9 These findings therefore provide a preclinical and clinical rationale for the potential use of the fasting-mimicking diet as a nutritional strategy in prostate cancer.
The study10, conducted by the research group led by V. Fay-Watt in collaboration with Professor Longo and published in March 2023 in the journal Prostate Cancer and Prostatic Diseases, aimed to examine whether three consecutive cycles of the fasting-mimicking diet (one cycle per month) could be safely tolerated and completed by a cohort of patients with prostate cancer. The authors evaluated the effect of the fasting-mimicking diet on metabolic risk factors associated with an unfavorable prognosis and on the features of metabolic syndrome in 29 participants. Participants were instructed to consume only the contents of a fasting-mimicking diet kit, a plant-based, low-protein meal-replacement regimen lasting four consecutive days. The dietary protocol provided approximately 1,100 kcal on the first day, derived from 30% carbohydrates, 61% fats, and 9% proteins, and approximately 900 kcal in total on each of the following days (days 2–4), when complex carbohydrates became the main macronutrient (>80% of energy) and fats accounted for approximately 10% of energy intake. After completing the regimen, participants returned to their usual diet until the next cycle. The participants ultimately completed three cycles of the fasting-mimicking diet and were assessed at baseline (before starting the intervention) and at least three months after completing the last cycle, to allow for a washout period and thus assess whether the clinical effects could be maintained over time. The primary study outcomes were body weight, waist circumference, and blood pressure. Secondary outcomes included several metabolic markers assessed through blood tests: fasting blood glucose, total cholesterol, HDL and LDL cholesterol, triglycerides, glycated hemoglobin (HbA1c), prostate-specific antigen (PSA), and other metabolic and inflammatory markers available in a subgroup of patients.
No significant adverse effects were observed in the cohort. Changes in risk factors and metabolic markers were assessed three months after the completion of three consecutive cycles of the fasting-mimicking diet. Following the intervention, several metabolic parameters improved: patients’ body weight decreased by 3.79 kg at the 3-month follow-up, waist circumference decreased by an average of 4.57 cm, and the fasting-mimicking diet cycles were also associated with a reduction in systolic blood pressure (BP), with a mean difference of −9.52 mmHg, while diastolic blood pressure decreased by 4.48 mmHg. We believe that the study demonstrated promising improvements in metabolic risk factors (body weight, waist circumference, and blood pressure), potentially relevant to the overall outcome of patients with prostate cancer, especially those with significant metabolic impairment due to ADT.
To further assess the efficacy of the fasting-mimicking diet on metabolic risk factors, a subgroup analysis was performed to compare changes across groups stratified according to the baseline levels of each risk factor. The fasting-mimicking diet significantly reduced body mass index (BMI) and waist circumference in all subgroups, with a greater reduction in abdominal obesity among participants who were obese at baseline (BMI ≥ 30). Similarly, the reduction in HbA1c was greater in patients with dysglycemia or prediabetes (baseline HbA1c ≥ 42 mmol/mol), and the reduction in triglycerides was greater in patients with hypertriglyceridemia (baseline values > 1.7 mmol/L). Participants with baseline systolic blood pressure ≥ 130 mmHg experienced a greater reduction following the fasting-mimicking diet than those with values < 130 mmHg. Diastolic blood pressure remained unchanged in participants with baseline values < 85 mmHg, but decreased in those with values ≥ 85 mmHg. Total cholesterol decreased significantly in patients with baseline levels < 5.2 mmol/L, but not in those with levels ≥ 5.2 mmol/L. The fasting-mimicking diet did not affect HDL cholesterol levels in participants, regardless of whether their baseline levels were above or below 1 mmol/L. Overall, these findings suggest that cycles of the fasting-mimicking diet are more effective across most of the parameters assessed in patients at higher risk of metabolic syndrome.
Most participants reported that the intervention was easy to complete, with completion rates of 83% for three cycles, 91% for two cycles, and 100% for one cycle. Importantly, no adverse effects attributable to the fasting-mimicking diet were observed. The withdrawal of six of the 35 enrolled participants, some of whom experienced difficulties adhering to the fasting-mimicking diet protocol, is consistent with findings from other similar studies.11
The persistence of the fasting-mimicking diet’s effects on metabolic markers for more than three months after its completion highlights the potential benefits of completing even a single cycle. Therefore, even patients who are unable to complete three consecutive cycles of the fasting-mimicking diet but manage to complete fewer cycles may still benefit from the intervention, a possibility that should be verified in future clinical studies.
This study has several limitations, including the small cohort size, the heterogeneity of patients in terms of disease stage and extent, and differences in treatment phase. Moreover, although participants were instructed not to make changes to their diet or lifestyle throughout the study, except during the days of the fasting-mimicking diet regimen, some reported voluntarily making changes after experiencing the benefits of the intervention and gaining a better understanding of the importance of dietary choices in the context of their disease. It is therefore not possible to determine whether the observed benefits can be attributed exclusively to the intervention, and further studies are needed to investigate this possibility. Overall, the study suggests that the fasting-mimicking diet is a safe and promising approach to improving metabolic health in patients with prostate cancer.
Suggested reading: Valter Longo. Fasting Cancer: How Fasting and Nutritechnology Are Creating a Revolution in Cancer Prevention and Treatment. Avery, 2025.